B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
Atripla (ATP: FTC/TDF/EFV) was the first single pill treatment for HIV and was the most
prescribed first-line treatment from approximately 2008 to 2013 for people infected with HIV.
However, ATP has not been recommended as a "preferred" treatment for HIV since 2015, due to
there now being single pill treatments that work better. There are a lot of people who are
still taking ATP and it is working for them. However, it has the potential to cause serious
side effects (chronic kidney disease and fractures and serious neurological effects). These
side effects are caused by components in ATP (namely the TDF and EFV parts). Also, the
efavirenz (EFV) component is not compatible for treatment of Hepatitis C (HCV) - which is
often also seen in people who have HIV. For these reasons, there is a need to find a better
alternative treatment for these people currently being treated with ATP.
Phase:
Phase 4
Details
Lead Sponsor:
University of Alberta
Collaborators:
Gilead Sciences University of British Columbia
Treatments:
Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Tenofovir